STOCKHOLM, Feb. 12, 2020 /PRNewswire/ -- "2019 was the year
when Alligator entered the clinical phase on a broad front. At the
beginning of the year, we had one clinical project and at year-end,
the number had increased to four", commented CEO Per
Norlén.
Significant events October - December
- The first patient was dosed in a Phase I study with the drug
candidate ATOR-1017 that is in development for the treatment of
metastasized cancer.
- Dr Malin Carlsson was appointed
Chief Operating Officer.
- ALG.APV-527 and ATOR-1017 new preclinical data were presented
at the scientific conference SITC 2019.
Events after the end of the period
- ATOR-1015: The Phase I clinical trial is progressing well with
nine dose levels evaluated for initial safety. Currently,
evaluation of 400 mg dosing, about 6 mg/kg given every two
weeks, is initiated.
Financial information
October - December 2019
- Net sales, SEK 0.0 million
(25.6)
- Total operating costs SEK -59.7
million (-56.1)
- Operating result, SEK -59.3
million (-30.1)
- Earnings per share before and after dilution, SEK -0.84 (-0.43)
- Cash flow for the period, SEK -41.5
million (-41.8)
- Cash, cash equivalents, incl securities, SEK 249.9 million (436.4)
January - December 2019
- Net sales, SEK 4.4 million
(27.0)- Total operating costs SEK -219.9
million (-181.6)- Operating result, SEK -214.5 million (-153.1)- Earnings per share
before and after dilution, SEK -2.94
(-2.10)- Cash flow for the period, SEK
-167.5 million (-111.8)
Read the complete report in the pdf below.
Conference call
All interested parties are invited to participate in a telephone
conference, which will include a presentation of the
Year-end report. The event will be hosted by CEO Per Norlén and the presentation will be held in
English.
When: 09:00 a.m. CET Wednesday February 12, 2020.
Listen to the
presentation: https://tv.streamfabriken.com/alligator-bioscience-q4-2019
To participate in the telephone conference, please use the dial
in details shown below:
SE: +46856642703
UK: +443333009264
US: +18338230589
The conference call will be made available on the company's
website after the call.
For further information, please contact:
Per Norlén, CEO, per.norlen@alligatorbioscience.com,
+46-46-540-82-00.
Per-Olof Schrewelius,
CFO, per-olof.schrewelius@alligatorbioscience.com,
+46-46-540-82-03.
Cecilia Hofvander, Director IR
&
Communications, cecilia.hofvander@alligatorbioscience.com,
+46-46-540-82-06.
Alligator Bioscience AB (publ) 556597-8201
Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden
Phone +46-46-540-82-00
www.alligatorbioscience.com
This information is such information as Alligator Bioscience
AB (publ) is obliged to make public pursuant to the EU Market Abuse
Regulation. The information was submitted for publication, through
the agency of the contact persons set out above, at 8:00 a.m.
CET on February 12,
2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's growing pipeline includes six lead clinical and
preclinical drug candidates: mitazalimab (ADC-1013), ATOR-1015,
ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics
Inc.), ATOR-1144 and AC101 (in clinical development by Shanghai
Henlius Biotech Inc.). Alligator's shares are listed on Nasdaq
Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55
employees. For more information, please visit
www.alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-ab-year-end-report-january-december-2019,c3032984
The following files are available for download:
|
https://mb.cision.com/Main/12681/3032984/1192101.pdf
|
Alligator Bioscience:
Year-end Report January-December 2019
|
View original
content:http://www.prnewswire.com/news-releases/alligator-bioscience-ab-year-end-report-january-december-2019-301003507.html
SOURCE Alligator Bioscience